| Name | TMI-1 |
| Description | TMI-1 (WAY-171318), a novel orally active inhibitor of ADAM17 (TACE) and MMP, induces tumor apoptosis in a breast cancer. |
| In vitro | TMI 1 inhibits LPS-induced TNF-α secretion in Raw and THP-1 cells (IC50s = 40 and 200 nM, respectively), as well as in isolated human monocytes and whole blood (IC50s = 190 and 300 nM, respectively).[1]
It inhibits the production of TNF-α ex vivo in synovium isolated from the inflamed joints of patients with rheumatoid arthritis with IC50 values of less than 100 nM without inhibiting TNF-α expression in vitro.[3] |
| In vivo | TMI 1 inhibits LPS-induced TNF-α production in mice (ED50 = 5 mg/kg) and reduces disease severity in mouse models of collagen-induced arthritis. It also decreases cell viability of (ED50s = 1.3-8.1 μM), and induces caspase-3/7 activity in, a variety of cancer cell lines and induces tumor apoptosis and reduces tumor growth in an MMTV-ErbB2/neu mouse model of breast cancer when administered at a dose of 100 mg/kg.[3] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 35.9 mg/mL (90.09 mM), Sonication is recommended.
|
| Keywords | WAY171318 | WAY 171318 | TMI-1 | TMI1 | TMI 1 | apoptosis | ADAM17 |
| Inhibitors Related | Kaolin | Stavudine | Aceglutamide | Urea | Tamoxifen | D(+)-Raffinose pentahydrate | Metronidazole | Hydroxypropyl Cellulose | Doxycycline | Formamide | Gluconate Calcium | Alginic acid |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Protease Inhibitor Library | Inhibitor Library | Anti-Fibrosis Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
